Coherus Oncology, Inc. (CHRS)

Import this data to Google Sheets with:

=jivedata("CHRS","financials")

Full statements spill as a table. For one cell: =jivedata("CHRS","Revenue") or =jivedata("CHRS","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Coherus Oncology, Inc.

CHRS • CIK 0001512762

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Revenue from Contract with Customer, Including Assessed Tax	$257,244	$266,960	$42,172	$50,936
Operating Income (Loss)	$-203,199	$-111,667	$-181,134	$-158,695
Interest Expense	$40,542	$27,158	$9,001	$9,083
Gain (Loss) on Extinguishment of Debt	$-6,222	$-12,630	$0	$0
Other Nonoperating Income (Expense)	$5,469	$3,373	$7,011	$6,632
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$-238,272	$28,507	$-183,124	$-161,146
Income Tax Expense (Benefit)	$-380	$-380	$0	$0
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	—	—	$-183,124	$-161,146
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	—	—	$351,148	$29,014
Net Income (Loss) Attributable to Parent	$-237,892	$28,507	$168,024	$-132,132
Cost of Goods and Services Sold	$158,992	$117,553	$13,814	$15,822
Research and Development Expense	$109,436	$93,336	$108,888	$101,211
Selling, General and Administrative Expense	$192,015	$167,738	$100,604	$92,598
Costs and Expenses	$460,443	$378,627	$223,306	$209,631
Weighted Average Number of Shares Outstanding, Basic	94,162,637	114,553,537	117,143,457	146,833,592
Weighted Average Number of Shares Outstanding, Diluted	94,162,637	114,830,462	117,143,457	146,833,592

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$102,891	$125,987	$88,879	$82,923
Marketable Securities, Current	$14,857	$14,857	$83,246	$22,383
Property, Plant and Equipment, Net	$5,119	$2,837	$1,345	$1,345
Receivables, Net, Current	$260,522	$111,324	$17,815	$13,881
Inventory, Noncurrent	$67,495	$43,776	$0	$8,425
Intangible Assets, Net (Including Goodwill)	$71,673	$53,646	$46,239	$44,989
Inventory, Net	$62,605	$70,094	$3,172	$5,667
Other Assets, Noncurrent	$9,686	$6,691	$4,053	$3,116
Disposal Group, Including Discontinued Operation, Assets, Noncurrent	—	—	$44,243	$44,243
Prepaid Expense and Other Assets, Current	$11,099	$11,532	$6,233	$5,354
Assets	$629,604	$448,533	$258,343	$191,183
Disposal Group, Including Discontinued Operation, Assets, Current	—	—	$72,180	$72,180
Assets, Current	$475,631	$341,583	$206,706	$133,788
Convertible Subordinated Debt, Noncurrent	$226,888	$228,229	$228,229	$228,569
Other Liabilities, Noncurrent	$12,561	$29,329	$18,435	$17,588
Liabilities	$823,029	$580,523	$197,329	$130,345
Accounts Payable, Current	$35,219	$28,456	$9,915	$13,168
Employee-related Liabilities, Current	$21,521	$18,344	$14,579	$9,937
Accrued Liabilities, Current	$105,386	$60,288	$20,430	$14,851
Liabilities, Current	$331,771	$282,981	$140,386	$75,510
Common Stock, Value, Issued	$11	$12	$12	$15
Additional Paid in Capital	$1,386,312	$1,419,266	$1,444,166	$1,503,031
Accumulated Other Comprehensive Income (Loss), Net of Tax	$-248	$-275	$-195	$-281
Retained Earnings (Accumulated Deficit)	$-1,579,500	$-1,550,993	$-1,382,969	$-1,441,927
Stockholders' Equity Attributable to Parent	$-193,425	$-131,990	$61,014	$60,838
Preferred Stock, Shares Authorized	5,000,000	5,000,000	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	300,000,000	300,000,000	300,000,000	300,000,000
Common Stock, Shares, Issued	112,215,260	115,614,548	121,154,925	154,470,363

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$39,356	$22,907	$-37,131	$-133,993
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$103,343	$126,250	$89,119	$121,923
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-237,892	$28,507	$168,024	$-132,132
Net Cash Provided by (Used in) Operating Activities	$-174,884	$-20,440	$-138,513	$-186,031
Payments to Acquire Marketable Securities	$19,507	$19,507	$103,838	$103,397
Proceeds from Sale and Maturity of Marketable Securities	$144,360	$6,200	$21,462	$21,462
Proceeds from Sale of Debt Securities, Available-for-sale	$13,282	$8,688	$8,688	$8,688
Payments for (Proceeds from) Productive Assets	—	—	$-470,305	$-470,305
Payments for (Proceeds from) Other Investing Activities	—	$-110	$342	$1,139
Net Cash Provided by (Used in) Investing Activities	$144,640	$230,321	$375,087	$-9,779
Proceeds from Issuance of Debt	$240,679	—	—	—
Proceeds from Issuance of Private Placement	—	—	$7,894	$7,894
Proceeds from Issuance of Common Stock	—	—	$1,455	—
Proceeds from Stock Plans	$1,809	$926	$353	$367
Payment, Tax Withholding, Share-based Payment Arrangement	$3,587	$2,476	$283	$115
Repayments of Convertible Debt	$109,000	$109,000	$233,185	$121
Repayments of Debt	$81,750	—	$260,387	$260,387
Proceeds from (Payments for) Other Financing Activities	$-1,034	$-248	$-832	$142
Net Cash Provided by (Used in) Financing Activities	$69,600	$-186,974	$-273,705	$61,817
Interest Paid, Excluding Capitalized Interest, Operating Activities	$37,857	$25,376	$9,916	$9,916
Income Taxes Paid, Net	$-118	$-114	$36	$36
Stock Issued	—	$4,408	$4,408	$4,408
Depreciation, Depletion and Amortization, Nonproduction	$3,791	$5,276	$3,924	$3,605
Share-based Payment Arrangement, Noncash Expense	$43,110	$27,802	$16,966	$11,141
Gain (Loss) on Sale of Interest in Projects	—	$176,589	$338,315	$-1,486
Inventory Write-down	$52,595	$14,143	$14,143	$14,143
Other Operating Activities, Cash Flow Statement	$-1,493	$-5,471	$-10,328	$-24,848
Increase (Decrease) in Receivables	$150,683	$-149,350	$-93,557	$8,664
Increase (Decrease) in Inventories	$46,734	$31,952	$17,108	$9,509
Increase (Decrease) in Prepaid Expense	$-2,027	$-4,664	$-338	$-4,635
Increase (Decrease) in Prepaid Expense and Other Assets	$-16,155	$838	$-4,772	$-10,209
Increase (Decrease) in Accounts Payable, Trade	$23,760	$-3,938	$-19,556	$-16,136
Increase (Decrease) in Other Operating Assets and Liabilities, Net	—	—	$-64,446	$-32,819
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities	$10,917	$-56,876	$-9,199	$-2,734

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("CHRS","financials")

Full statements spill as a table. For one cell: =jivedata("CHRS","Revenue") or =jivedata("CHRS","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.